Maxpro Capital Acquisition (JMAC) Competitors $5.95 +0.06 (+1.02%) As of 04/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JMAC vs. RGNX, TKNO, ALLO, TRDA, PHAT, OLMA, ATAI, HRTX, CYRX, and ARCTShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include REGENXBIO (RGNX), Alpha Teknova (TKNO), Allogene Therapeutics (ALLO), Entrada Therapeutics (TRDA), Phathom Pharmaceuticals (PHAT), Olema Pharmaceuticals (OLMA), Atai Life Sciences (ATAI), Heron Therapeutics (HRTX), Cryoport (CYRX), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. REGENXBIO Alpha Teknova Allogene Therapeutics Entrada Therapeutics Phathom Pharmaceuticals Olema Pharmaceuticals Atai Life Sciences Heron Therapeutics Cryoport Arcturus Therapeutics REGENXBIO (NASDAQ:RGNX) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation. Is RGNX or JMAC more profitable? Maxpro Capital Acquisition has a net margin of 0.00% compared to REGENXBIO's net margin of -283.19%. Maxpro Capital Acquisition's return on equity of 0.00% beat REGENXBIO's return on equity.Company Net Margins Return on Equity Return on Assets REGENXBIO-283.19% -70.65% -41.68% Maxpro Capital Acquisition N/A N/A N/A Does the MarketBeat Community believe in RGNX or JMAC? REGENXBIO received 443 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformREGENXBIOOutperform Votes44365.44% Underperform Votes23434.56% Maxpro Capital AcquisitionN/AN/A Which has preferable valuation and earnings, RGNX or JMAC? Maxpro Capital Acquisition has lower revenue, but higher earnings than REGENXBIO. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioREGENXBIO$83.33M3.57-$263.49M-$4.61-1.29Maxpro Capital AcquisitionN/AN/AN/AN/AN/A Do institutionals and insiders hold more shares of RGNX or JMAC? 88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 13.1% of REGENXBIO shares are owned by insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor RGNX or JMAC? In the previous week, REGENXBIO had 15 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 15 mentions for REGENXBIO and 0 mentions for Maxpro Capital Acquisition. REGENXBIO's average media sentiment score of 1.14 beat Maxpro Capital Acquisition's score of 0.00 indicating that REGENXBIO is being referred to more favorably in the media. Company Overall Sentiment REGENXBIO Positive Maxpro Capital Acquisition Neutral Which has more volatility & risk, RGNX or JMAC? REGENXBIO has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Do analysts rate RGNX or JMAC? REGENXBIO presently has a consensus price target of $31.63, suggesting a potential upside of 432.41%. Given REGENXBIO's stronger consensus rating and higher possible upside, equities analysts plainly believe REGENXBIO is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryREGENXBIO beats Maxpro Capital Acquisition on 9 of the 13 factors compared between the two stocks. Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$79.90M$456.56M$1.98B$7.35BDividend YieldN/A8.15%2.76%4.31%P/E RatioN/A2.4122.4117.82Price / SalesN/A58.3462.0597.68Price / CashN/A69.0151.7234.64Price / BookN/A3.661.973.98Net IncomeN/A$35.22M-$385.85M$247.81M7 Day Performance0.08%2.78%0.52%3.19%1 Month Performance-25.25%-0.39%-5.18%-7.70%1 Year Performance1,160.59%21.62%4.59%1.49% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$5.95+1.0%N/A+1,160.6%$79.90MN/A0.002,021RGNXREGENXBIO4.6768 of 5 stars$6.16-6.0%$31.88+417.5%-62.1%$308.72M$83.33M-1.22370Analyst ForecastAnalyst RevisionNews CoveragePositive NewsTKNOAlpha Teknova1.5011 of 5 stars$5.77-1.0%$8.50+47.3%+188.0%$308.33M$37.75M-7.80240Positive NewsGap UpALLOAllogene Therapeutics3.0395 of 5 stars$1.40-4.1%$9.29+563.5%-58.2%$304.17M$22,000.00-0.90310News CoverageTRDAEntrada Therapeutics2.8343 of 5 stars$7.86-0.1%$25.67+226.5%-33.1%$295.50M$210.78M4.94110Positive NewsPHATPhathom Pharmaceuticals3.5599 of 5 stars$4.22-11.5%$22.17+425.3%-55.1%$293.87M$55.25M-0.74110Analyst ForecastNews CoverageOLMAOlema Pharmaceuticals2.8738 of 5 stars$4.26+1.2%$27.67+549.5%-55.5%$291.10MN/A-1.9570Short Interest ↓Positive NewsATAIAtai Life Sciences1.8838 of 5 stars$1.42+2.2%$10.50+639.4%-20.5%$281.60M$308,000.00-1.7580HRTXHeron Therapeutics3.5401 of 5 stars$1.84-4.2%$5.67+208.0%-30.3%$280.29M$144.29M-10.22300Positive NewsCYRXCryoport2.5286 of 5 stars$5.61-0.2%$11.67+108.0%-65.6%$280.00M$228.39M-1.661,020Analyst ForecastAnalyst RevisionNews CoverageARCTArcturus Therapeutics2.7389 of 5 stars$10.30-2.6%$59.20+474.8%-59.5%$279.34M$138.39M-4.64180Analyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies RGNX Competitors TKNO Competitors ALLO Competitors TRDA Competitors PHAT Competitors OLMA Competitors ATAI Competitors HRTX Competitors CYRX Competitors ARCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JMAC) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JMAC Stock Free JMAC Stock Alerts